Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 17, 2020 - Issue 4
Submit an article Journal homepage
221
Views
14
CrossRef citations to date
0
Altmetric
Original Research

Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles

Binquan WuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, ChinaView further author information
,
Amin LiBiochemistry Department, Medical School, Anhui University of Science & Technology, Huainan, ChinaView further author information
,
Yinci ZhangBiochemistry Department, Medical School, Anhui University of Science & Technology, Huainan, ChinaView further author information
,
Xueke LiuBiochemistry Department, Medical School, Anhui University of Science & Technology, Huainan, ChinaView further author information
,
Shuping ZhouBiochemistry Department, Medical School, Anhui University of Science & Technology, Huainan, ChinaView further author information
,
Huaiyong GanDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, ChinaView further author information
,
Shiyu CaiBiochemistry Department, Medical School, Anhui University of Science & Technology, Huainan, ChinaView further author information
,
Yong LiangCentral Laboratory, Huai’an Hospital Affiliated of Xuzhou Medical College and Huai’an Second Hospital, Huai’an, P. R. ChinaCorrespondence[email protected]
View further author information
&
Xiaolong TangDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China;Biochemistry Department, Medical School, Anhui University of Science & Technology, Huainan, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 573-587 | Received 09 Jan 2020, Accepted 13 Feb 2020, Published online: 23 Feb 2020

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Fangshu Liu, Lei Meng, Heran Wang, Chenchen Du, Jiaying Zhu, Qian Xiong & Weitong Sun. (2023) Research on preparation and antitumor activity of redox-responsive polymer micelles co-loaded with sorafenib and curcumin. Journal of Biomaterials Science, Polymer Edition 34:16, pages 2179-2197.
Read now
Xin Zhou, Tian-Man Li, Jian-Zhu Luo, Chen-Lu Lan, Zhong-Liu Wei, Tian-Hao Fu, Xi-Wen Liao, Guang-Zhi Zhu, Xin-Ping Ye & Tao Peng. (2021) CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27kip1 Axis. Journal of Hepatocellular Carcinoma 8, pages 1323-1338.
Read now
Huajing Yang, Hui Jing, Xue Han, Haoyan Tan & Wen Cheng. (2021) Synergistic Anticancer Strategy of Sonodynamic Therapy Combined with PI-103 Against Hepatocellular Carcinoma. Drug Design, Development and Therapy 15, pages 531-542.
Read now

Articles from other publishers (11)

Muhammed Mehdi Üremiş, Nuray Üremiş & Yusuf Türköz. (2023) Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways. Steroids 198, pages 109261.
Crossref
Li Song, Ruyue Xu, Wenpeng Cai, Jiaojiao Liang, Niandie Cao, Jiafeng Gao & Xiaolong Tang. (2023) IL ‐6 upregulates the expression of IL‐6R through the JAK2 / STAT3 signalling pathway to promote progression of hepatocellular carcinoma . Scandinavian Journal of Immunology 98:1.
Crossref
Reena Gupta, Mustafa M. Kadhim, Abduladheem Turki Jalil, Ali Mohammed Obayes, Zafar Aminov, Fahad Alsaikhan, Andrés Alexis Ramírez-Coronel, Pushpamala Ramaiah, Nahla A. Tayyib & Xuanming Luo. (2023) Multifaceted role of NF-κB in hepatocellular carcinoma therapy: Molecular landscape, therapeutic compounds and nanomaterial approaches. Environmental Research 228, pages 115767.
Crossref
Mahshid Deldar Abad Paskeh, Fatemeh Ghadyani, Mehrdad Hashemi, Alireza Abbaspour, Amirhossein Zabolian, Salar Javanshir, Mehrnaz Razzazan, Sepideh Mirzaei, Maliheh Entezari, Mohammad Ali Shekhi Beig Goharrizi, Shokooh Salimimoghadam, Amir Reza Aref, Alireza Kalbasi, Romina Rajabi, Mohsen Rashidi, Afshin Taheriazam & Gautam Sethi. (2023) Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: Promises and Challenges. Pharmacological Research 187, pages 106553.
Crossref
Feixiang Luo, Ying Yu, Mingqian Li, Yuguo Chen, Peng Zhang, Chunsheng Xiao & Guoyue Lv. (2022) Polymeric nanomedicines for the treatment of hepatic diseases. Journal of Nanobiotechnology 20:1.
Crossref
Le Yu, Jessica Wei & Pengda Liu. (2022) Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Seminars in Cancer Biology 85, pages 69-94.
Crossref
Shuping Zhou, Yongfang Ma, Ruyue Xu & Xiaolong Tang. (2022) Nanoparticles Loaded with GSK1059615 Combined with Sorafenib Inhibited Programmed Cell Death 1 Ligand 1 Expression by Negatively Regulating the PI3K/Akt/NF- κ B Pathway, Thereby Reversing the Drug Resistance of Hepatocellular Carcinoma to Sorafenib . Journal of Biomedical Nanotechnology 18:3, pages 693-704.
Crossref
Mohamed Fawzi Kabil, Maha Nasr & Ibrahim M. El-Sherbiny. (2021) Conventional and hybrid nanoparticulate systems for the treatment of hepatocellular carcinoma: An updated review. European Journal of Pharmaceutics and Biopharmaceutics 167, pages 9-37.
Crossref
Huili Lai, Liping Zhong, Yong Huang, Yongxiang Zhao & Zhiyong Qian. (2021) Progress in Application of Nanotechnology in Sorafenib. Journal of Biomedical Nanotechnology 17:4, pages 529-557.
Crossref
Shuping Zhou, Yongfang Ma, Xueke Liu, Pan Yu, Ning Huang, Li Song, Ruyue Xu, Zhen Huo, Tao Zhu & Xiaolong Tang. (2021) Targeted Delivery of Glypican 3 (GPC3) Antibody-Modified MicroRNA (miR let-7b-5p) Polymer Nanoparticles to Sorafenib-Resistant Hepatsocellular Carcinoma Cells. Journal of Biomedical Nanotechnology 17:4, pages 677-690.
Crossref
Yi-Ting Hu, Zhe-Yue Shu, Jing-Hua Jiang, Qin-Fen Xie & Shu-Sen Zheng. (2020) Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells. Hepatobiliary & Pancreatic Diseases International 19:6, pages 547-554.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.